-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 18, Luye Pharmaceuticals announced that its subsidiary Luye Pharmaceuticals (Switzerland) and Towa Pharmaceutical have reached an agreement to grant the latter the exclusive right to develop and commercialize Lisz’s Mingta day transdermal patch in the Japanese market.
Liss' Mindo Day transdermal patch is used to treat Alzheimer's disease and is an innovative preparation independently developed by Luye Pharma.
At present, the application for marketing of Liss' Mingdori transdermal patch in Europe has been accepted by the European Union authorities, and it has entered the clinical stage in China, and will soon enter the phase III clinical trial in Japan.
According to the agreement, Donghe Pharmaceuticals will obtain the exclusive right to develop and commercialize Liss’ Mindori transdermal patches in the Japanese market.
Alzheimer's disease has become a major health problem worldwide.
Note: The original text has been deleted